# Twist Bioscience Corporation Common Stock (TWST) — Stock CV

Twist Bioscience Corporation is a $10.7B healthcare company. Revenue grew 19.2% over the last year, and it currently loses money.

> Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

## Identity

- **Ticker**: TWST
- **Sector**: Healthcare
- **Industry**: Biological Products, (No Diagnostic Substances)
- **Headquarters**: SOUTH SAN FRANCISCO, CA
- **Employees**: 979
- **Website**: https://www.twistbioscience.com
- **Market cap**: $10.7B
- **Last price**: $161.77
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $432M
- **Net income**: -$137M
- **Free cash flow**: -$93.1M
- **Revenue growth (YoY)**: 19.2%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 20 |
| Growth | 25 |
| Profitability | 0 |
| Health | 50 |
| Quality | 35 |
| Moat | 13 |

## Qualifications (beginner checklist) — 5 of 9 passed

- [x] Revenue growing — +19.2% YoY
- [ ] Profitable — -$137M TTM
- [x] Profit growing — +62.8% YoY
- [ ] Generates cash — -$93.1M TTM
- [x] Debt under control — current ratio 2.67
- [x] Established company — $10.7B market cap
- [ ] Not printing shares — +11.0% shares over ~5y
- [ ] Proven track record — 0/7 profitable years
- [x] Financially stable — Altman Z 24.2 — safe

## Experience (career milestones)

- **2021** — Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design
- **2013** — Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck

## Strengths

- High gross margin (52.0%)
- Revenue growing 19.2% year over year
- Altman Z-Score 24.18 — low bankruptcy-risk zone

## Watch-outs

- Not profitable — 31.7% net margin
- Negative free cash flow (-$93.1M)
- Thin interest coverage (-235.7×)
- Loss-making in 7 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $132M | -$152M | -$139M |
| FY2022 | $204M | -$218M | -$226M |
| FY2023 | $245M | -$205M | -$170M |
| FY2024 | $313M | -$209M | -$69.2M |
| FY2025 | $377M | -$77.7M | -$75.6M |

---

Source: https://stockcv.com/TWST — derived from company filings; may be delayed or incomplete. Information, not investment advice.